Suppr超能文献

鞘氨醇激酶 2 促进胰岛β细胞的脂毒性和糖尿病的进展。

Sphingosine kinase 2 promotes lipotoxicity in pancreatic β-cells and the progression of diabetes.

机构信息

Department of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China; and.

出版信息

FASEB J. 2019 Mar;33(3):3636-3646. doi: 10.1096/fj.201801496R. Epub 2018 Nov 19.

Abstract

Loss of functional β-cell mass caused by lipotoxicity is a key pathogenic factor in the development of type 2 diabetes mellitus (T2DM). We have previously reported that sphingosine kinase (SK)1 is an endogenous protector of β-cells against lipotoxicity. The current study reports that SK2, another isoform of SK, is a crucial mediator of lipotoxicity in β-cells. Exposure of β-cells to palmitatic acid (PA), a saturated free fatty acid, resulted in a nearly 2-fold increase in SK2 expression, which paralleled the induction of cell death in a similar dose- and time-dependent fashion. Silencing SK2 expression by its specific small interfering RNAs significantly inhibited PA-induced cell death and caspase-3 activation, whereas overexpression of SK2 promoted lipotoxicity in β-cells. Mechanistically, upon exposure to PA, endogenous SK2 was shuttled from the nucleus to the cytoplasm, where it interacted with B-cell lymphoma-extra-large (Bcl-xL), leading to mitochondrial apoptotic pathway activation and cell death. By blocking SK2 translocation and its interaction with Bcl-xL, either the nuclear export signal mutant (L423A/L425A) or the BH3 domain mutant (L219A) of SK2 significantly attenuated β-cell lipotoxicity. Furthermore, SK2 deficiency in mice significantly prevented the loss of β-cell mass, preserved insulin production, and ameliorated the diabetic phenotype in an established T2DM model induced by feeding a high-fat diet accompanied by administration of streptozotocin. These findings provide the first evidence, in vitro and in vivo, of a critical role for SK2 in mediating β-cell lipotoxicity and the progression of diabetes.-Song, Z., Wang, W., Li, N., Yan, S., Rong, K., Lan, T., Xia, P. Sphingosine kinase 2 promotes lipotoxicity in pancreatic β-cells and the progression of diabetes.

摘要

脂毒性引起的功能性β细胞数量减少是 2 型糖尿病(T2DM)发病的关键致病因素。我们之前的研究报道,鞘氨醇激酶(SK)1 是β细胞抵抗脂毒性的内源性保护剂。本研究报道,SK2 是 SK 的另一种同工酶,是β细胞脂毒性的关键介质。β细胞暴露于棕榈酸(PA),一种饱和游离脂肪酸,导致 SK2 表达增加近 2 倍,细胞死亡的诱导也呈相似的剂量和时间依赖性。其特异性小干扰 RNA 沉默 SK2 表达可显著抑制 PA 诱导的细胞死亡和半胱天冬酶-3 的激活,而过表达 SK2 则促进β细胞的脂毒性。机制上,PA 暴露后,内源性 SK2 从核内易位到细胞质,与 B 细胞淋巴瘤-extra-large(Bcl-xL)相互作用,导致线粒体凋亡途径的激活和细胞死亡。通过阻断 SK2 易位及其与 Bcl-xL 的相互作用,SK2 的核输出信号突变体(L423A/L425A)或 BH3 结构域突变体(L219A)显著减弱了β细胞的脂毒性。此外,SK2 敲除小鼠可显著防止β细胞数量减少,维持胰岛素的产生,并改善高脂饮食喂养联合链脲佐菌素给药建立的 T2DM 模型中的糖尿病表型。这些发现为 SK2 在介导β细胞脂毒性和糖尿病进展中的关键作用提供了体外和体内的首个证据。

相似文献

1
Sphingosine kinase 2 promotes lipotoxicity in pancreatic β-cells and the progression of diabetes.
FASEB J. 2019 Mar;33(3):3636-3646. doi: 10.1096/fj.201801496R. Epub 2018 Nov 19.
3
Fetuin A promotes lipotoxicity in β cells through the TLR4 signaling pathway and the role of pioglitazone in anti-lipotoxicity.
Mol Cell Endocrinol. 2015 Sep 5;412:1-11. doi: 10.1016/j.mce.2015.05.014. Epub 2015 May 15.
4
Sirtuin 5 overexpression attenuates glucolipotoxicity-induced pancreatic β cells apoptosis and dysfunction.
Exp Cell Res. 2018 Oct 1;371(1):205-213. doi: 10.1016/j.yexcr.2018.08.011. Epub 2018 Aug 8.
7
Sterol regulatory element-binding protein-1c knockdown protected INS-1E cells from lipotoxicity.
Diabetes Obes Metab. 2010 Jan;12(1):35-46. doi: 10.1111/j.1463-1326.2009.01093.x. Epub 2009 Sep 16.
8
Diet-induced β-cell insulin resistance results in reversible loss of functional β-cell mass.
FASEB J. 2019 Jan;33(1):204-218. doi: 10.1096/fj.201800826R. Epub 2018 Jun 29.
10
In vitro and in vivo roles of sphingosine kinase 2 during dengue virus infection.
J Gen Virol. 2019 Apr;100(4):629-641. doi: 10.1099/jgv.0.001245. Epub 2019 Mar 14.

引用本文的文献

1
Opaganib Promotes Weight Loss and Suppresses High-Fat Diet-Induced Obesity and Glucose Intolerance.
Diabetes Metab Syndr Obes. 2025 Apr 1;18:969-983. doi: 10.2147/DMSO.S514548. eCollection 2025.
2
Sphingosine kinase 2 and p62 regulation are determinants of sexual dimorphism in hepatocellular carcinoma.
Mol Metab. 2024 Aug;86:101971. doi: 10.1016/j.molmet.2024.101971. Epub 2024 Jun 24.
3
Sphingosine Kinase 2 Knockout Mice Resist HFD-Induced Obesity Through Increasing Energy Expenditure.
Int J Endocrinol Metab. 2023 Jul 30;21(3):e136539. doi: 10.5812/ijem-136539. eCollection 2023 Jul.
4
Characterization of a S1PR2 specific C-labeled radiotracer in streptozotocin-induced diabetic murine model.
Nucl Med Biol. 2023 Jul-Aug;122-123:108370. doi: 10.1016/j.nucmedbio.2023.108370. Epub 2023 Jul 26.
5
ORMDL in metabolic health and disease.
Pharmacol Ther. 2023 May;245:108401. doi: 10.1016/j.pharmthera.2023.108401. Epub 2023 Mar 30.
6
The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers.
Biomolecules. 2023 Jan 13;13(1):168. doi: 10.3390/biom13010168.
9
Sphingosine-1 Phosphate Lyase Regulates Sensitivity of Pancreatic Beta-Cells to Lipotoxicity.
Int J Mol Sci. 2021 Oct 8;22(19):10893. doi: 10.3390/ijms221910893.
10
Identification of circulating sphingosine kinase-related metabolites for prediction of type 2 diabetes.
J Transl Med. 2021 Sep 16;19(1):393. doi: 10.1186/s12967-021-03066-z.

本文引用的文献

3
Sphingosine-1-phosphate receptor 1 transmits estrogens' effects in endothelial cells.
Steroids. 2015 Dec;104:237-45. doi: 10.1016/j.steroids.2015.10.009. Epub 2015 Oct 22.
5
Sphingosine kinase (SphK) 1 and SphK2 play equivalent roles in mediating insulin's mitogenic action.
Mol Endocrinol. 2014 Feb;28(2):197-207. doi: 10.1210/me.2013-1237. Epub 2013 Jan 1.
7
Roles, regulation and inhibitors of sphingosine kinase 2.
FEBS J. 2013 Nov;280(21):5317-36. doi: 10.1111/febs.12314. Epub 2013 Jun 7.
8
Sphingolipid signaling in metabolic disorders.
Cell Metab. 2012 Oct 3;16(4):420-34. doi: 10.1016/j.cmet.2012.06.017. Epub 2012 Sep 13.
9
Experimentally induced rodent models of type 2 diabetes.
Methods Mol Biol. 2012;933:161-74. doi: 10.1007/978-1-62703-068-7_10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验